| Name | Title | Contact Details |
|---|
Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.